Welcome to our dedicated page for NovaBay Pharmaceuticals news (Ticker: $NBY), a resource for investors and traders seeking the latest updates and insights on NovaBay Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NovaBay Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NovaBay Pharmaceuticals's position in the market.
Rhea-AI Summary
NovaBay Pharmaceuticals, Inc. (NBY) partners with Woo University to educate eyecare professionals on amniotic membranes. The company recently launched Avenova® Allograft, a prescription amniotic membrane product. The partnership aims to support optometric continuing education through a free webinar featuring experts in the field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
-
Rhea-AI Summary
NBY: NovaBay® Pharmaceuticals Reports 7% Growth in Avenova® Product Revenue, 16% Narrowing of Operating Loss, and 7% Decline in Sales and Marketing Expenses. Company Expands Relationships with Eyecare Specialists and Promotes Avenova Allograft to U.S. Target Audience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.57%
Tags
-
Rhea-AI Summary
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) will report financial results for the three and nine months ended September 30, 2023 after market close on Thursday, November 9, 2023. An investment community conference call will be held on the same day at 4:30 p.m. Eastern time. Participants can pre-register for the conference call to receive a conference passcode and unique PIN. The live webcast of the conference call will be available on the Company website. A replay of the call will be available afterwards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
Rhea-AI Summary
NovaBay Pharmaceuticals launches new promotional programs for eyecare professionals
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.13%
Tags
-
Rhea-AI Summary
NovaBay Pharmaceuticals to present at Dawson James Small Cap Growth Conference, highlighting future strategies for eyecare, skincare, and wound care products
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
-
Rhea-AI Summary
NovaBay Pharmaceuticals launches Avenova Allograft in the US eyecare market, expected to compete in the $403.6 million ophthalmology amniotic membrane market. The product launch follows a previously announced agreement with BioStem Technologies. NovaBay's physician-dispensed channel continues to grow, providing a strong platform for the innovative product. Avenova Allograft is available in multiple sizes and aims to improve ocular surface health. NovaBay also offers a suite of other eyecare products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
Rhea-AI Summary
NovaBay Pharmaceuticals and BioStem Technologies announce agreement for commercialization of Amniotic Tissue Allograft
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.86%
Tags
-
Rhea-AI Summary
NovaBay Pharmaceuticals reports Q2 2023 financial results, with net product revenue of $4.6 million, a 26% increase YoY. Wound care sales reached a record quarterly high of $1.3 million. Sales and marketing expenses decreased by 16% through optimized digital marketing programs. Operating loss decreased by 37% YoY. Conference call to discuss results at 4:30 p.m. Eastern time today.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.85%
Tags
-
Rhea-AI Summary
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) will report financial results for the three and six months ended June 30, 2023 after market close on Thursday, August 10, 2023. An investment community conference call will be held on the same day at 4:30 p.m. Eastern time. Participants can pre-register for the conference call to gain immediate access and bypass the live operator. The live webcast of the conference call will be available on the Company website. A replay of the call will be available until August 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
NovaBay Pharmaceuticals, Inc.
NYSE:NBY
NBY Rankings
NBY Stock Data
3.42M
29.93M
0.04%
3.95%
2.39%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
EMERYVILLE
About NBY
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across